AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06683105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyIBDDiet app
Description: Participants in the Standard of Care arm will be administered the intervention (using the app) for 30 days, and participants in the MYIBDDiet arm will use the app for 60 days.
Study NCT06683833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egyptian MTA
Description: * Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Study NCT04052191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCRcI® stem cells
Description: Intra-Coronary Administration of MCRcI® stem cells
Study NCT06550349 — intervention group
Intervention type: OTHER
Intervention: N/A - non-interventional study
Description: N/A - non-interventional study. Data collection only.
Study NCT05156281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: tablet taken orally
Study NCT05156281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: capsule taken orally
Study NCT06683833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: * Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Study NCT06683833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide (Ca(OH)2)
Description: * Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Study NCT06682819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optical coherent tomography
Description: We compare the metabolomics profile of healthy patients based on the OCT appearance of the optic disc and RNFL
Study NCT06685419 — intervention group
Intervention type: OTHER
Intervention: Propolis containing gum
Description: Patients with moderate gingivitis will be asked to use gum containing propolis 5 times a day for a total of 3 weeks.
Study NCT06684561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIS
Description: All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.~defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.~if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users
Study NCT06682377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation alone
Description: No touch RFA with dual switching monopolar + bipolar mode
Study NCT06682767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMD1 (LNT22-017-1)
Description: FMD is a plant-based ketogenic diet that provides essential nutrients while maintaining hypo-caloric content. FMD is administered cyclically with 3-5 consecutive days of the diet followed by resumption of normal eating.
Study NCT06682715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: 10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
Study NCT06682715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
Study NCT06682715 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: nutrition education
Description: Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
Study NCT05302557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ileostomy stimulation
Description: Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
Study NCT05663866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.
Study NCT05663866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast will be administered orally.
Study NCT05663866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered subcutaneously.
Study NCT05663866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered intravenously.
Study NCT05663866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.
Study NCT05626088 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06592989 — intervention group
Intervention type: DRUG
Intervention: sorafenib, gefitinib
Description: Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.
Study NCT05043012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible AIR coil
Description: mpMRI scan
Study NCT05043012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endorectal coi
Description: mpMRI scan
Study NCT06657222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUB-030
Description: A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Study NCT06592794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1403
Description: Intramuscular (IM) injection.
Study NCT06592794 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution by IM injection.
Study NCT06605118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Injection
Description: 500mg azithromycin in 250 mL of normal saline
Study NCT06605118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL of normal saline
Study NCT06605118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Preoperative antibiotics
Description: standard of care preoperative antibiotics (excluding azithromycin) prior to incision
Study NCT06605118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Preoperative antibiotics
Description: standard of care preoperative antibiotics (excluding azithromycin) prior to incision
Study NCT05091853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesix mesh
Description: 2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
Study NCT06011551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ReGelTec HYDRAFIL™ System
Description: The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
Study NCT06011551 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conservative Care Management
Description: Conservative care management (including physical therapy and/or pain medication)
Study NCT06011551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Care Management
Description: Conservative care management (including physical therapy and/or pain medication)
Study NCT05351476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 300 Kcal worth of weight lifting, 3 times/week for 12 weeks
Study NCT05351476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise
Description: 300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
Study NCT06586255 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Immunotherapy and Radiation Therapy
Description: Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
Study NCT06682715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
Study NCT05761561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and medical nutrition
Description: The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight).
Study NCT06667076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.
Study NCT06667076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.
Study NCT06667076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Pemetrexed
Description: Pemetrexed will be administered through IV infusion.
Study NCT06667076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Carboplatin
Description: Carboplatin will be administered through IV infusion.
Study NCT06613529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online mindfulness training
Description: Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning.
Study NCT06614218 — intervention group
Intervention type: DEVICE
Intervention: Minimally Invasive Micro Sclerostomy
Description: The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
Study NCT05112939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA will be administered at different formulations.
Study NCT05112939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA will be administered at formulation 3.
Study NCT06619483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 1
Description: Single dose
Study NCT06619483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BAY3018250
Study NCT06619483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 2
Description: Single dose
Study NCT06622785 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)
Study NCT05325489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Budesonide
Description: use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD
Study NCT05325489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Budesonide Spray
Description: nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
Study NCT05412290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following.
Study NCT06622785 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise Benefits
Description: Data were collected using a Exercise Benefits/Barriers Scale .
Study NCT06127797 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire/Interview
Description: Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
Study NCT06624384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 drug
Description: Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
Study NCT06624384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Drug and placebo
Description: Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Study NCT06624384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: Drug and palcebo
Description: Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
Study NCT06625840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: Oral Administration
Study NCT06625840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Administration
Study NCT06625658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear aligner group
Description: aligner group change aligner every10 day
Study NCT06625489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: Placebo
Description: Placebo will be administered.
Study NCT06625489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib will be administered.
Study NCT04056741 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surfactant airway device
Description: Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
Study NCT06494410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High versus Low Fraction of Inspired Oxygen
Description: to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.
Study NCT05353244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrTMS
Description: Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.
Study NCT05353244 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
Study NCT05741853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Implemented Script Training for Aphasia (VISTA)
Description: Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
Study NCT05741853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical Retrieval Training (LRT)
Description: Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
Study NCT06137573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TNP-2198
Description: 600mg suspension containing 150μCi of \[14C\] TNP-2198
Study NCT05774665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
Study NCT05774665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).